It is also noteworthy that the recombinant human anti-vascular endothelial growth factor (VEGF) antibody Bevacizumab has entered clinical testing in COVID-19 patients with severe or critically severe pneumonia (BEST-RCT, ClinicalTrials.gov Identifier: NCT04305106) because of the potential contribution of VEGF to capillary leak in the lungs of patients with ARDS (Rosa, 2020). The gene discussed is VEGFA; the disease is susceptibility to pneumonia measurement.